Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of exebacase added to standard antibacterial therapy for Staphylococcus aureus bacteremia including endocarditis
2016-003059-31Phase 2Completed
- Sponsor
- ContraFect Corporation
- Start
- Jul 2017
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Staphylococcus aureus bloodstream infection (SABSI) and endocarditis (IE) comparing Exebacase + standard-of-care antibacterial therapy with Placebo + standard-of-care antibacterial therapy (2 arms). Started Jul 2017; status: completed.
02
Drugs
exebacase
03
Conditions
Staphylococcus aureus bloodstream infection (SABSI)endocarditis (IE)
Beyond the preview
Go deeper on 2016-003059-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003059-31.